Dear Investors:

Opus8 is hosting a virtual, invitation-only virtual private investor briefing featuring Maxwell Biosciences, a clinical-stage biotechnology company advancing a first-in-class Synthetic Immune System™ platform designed to transform the treatment of infectious diseases.

This closed-door session will provide direct access to Maxwell’s leadership team and an opportunity to review the company’s Claromer™ technology, extensive scientific and government validation, lead clinical strategy, and upcoming FDA milestones, as well as a discussion of current and future financing opportunities for accredited investors.

Maxwell is entering a critical value-creation phase, supported by strong Pre-IND FDA feedback and an anticipated IND submission in 2026, positioning the company for meaningful clinical and strategic inflection points. Maxwell is uniquely positioned at the intersection of antimicrobial resistance, biodefense preparedness, and next-generation anti-infectives—areas now prioritized by governments, regulators, and strategic pharma partners worldwide.

Company Overview
Maxwell Biosciences has developed an AI-driven drug discovery platform that creates synthetic small molecules designed to mimic LL-37, the human immune system’s primary antimicrobial peptide. Unlike traditional antibiotics, Maxwell’s Claromers™ are broadly effective against nearly all tested bacterial and fungal pathogens—including drug-resistant strains and biofilms—without inducing resistance.

The platform is supported by over $65 million in non-dilutive government grants and investor financing, more than 250 peer-reviewed scientific publications, and seven U.S. military Collaborative Research and Development Agreements. Maxwell’s lead clinical program is targeting Chronic Rhinosinusitis (CRS), with Phase 1 clinical trials anticipated in 2026.

What Differentiates Maxwell Biosciences
• First-in-Class Synthetic Immune System™ — Small molecules designed to replicate natural human immunity rather than target single pathogens
• Broad-Spectrum, Resistance-Free Activity — Demonstrated efficacy against hundreds of bacterial and fungal pathogens, including drug-resistant strains and biofilms
• AI-Driven Claromer™ Platform — Rapid creation of a scalable library of drug candidates across multiple infectious disease indications
• Strong Government & Military Validation — DARPA-seeded platform supported by $65M+ in non-dilutive funding and active U.S. defense and public health collaborations
• Compelling Regulatory & IP Profile — Encouraging FDA Pre-IND feedback, robust composition-of-matter patents, and high likelihood of Qualified Infectious Disease Product (QIDP) designation with extended market exclusivity
• Massive Market Opportunity — Positioned to address a global infectious disease market projected to exceed $190B, with platform-level expansion across pharma, government stockpiling, and strategic partnerships

Event Details
Date: Wednesday, January 21, 2026
Time: 11:30am - 12:30pm EST
Location: Online via Zoom

Attendance is strictly limited and curated.

Important Notes
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us for this important discussion.

Best,

Tien Wong
CEO, Opus8, Inc.
twong@opus8.com
M: 703-932-9191

Opus8 is hosting a small, invitation-only private investor briefing featuring Angiex, a clinical-stage oncology company advancing a first-in-class platform of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) for solid tumors.

This closed-door session will provide direct access to Angiex’s leadership team and an opportunity to review the company’s lead Phase 1 clinical program, emerging clinical signals, platform differentiation, and upcoming milestones, as well as a discussion of current financing opportunities for accredited investors.

Angiex is entering a critical value-creation phase, with early clinical data beginning to inform downstream strategic and capital formation decisions.

Company Overview

Angiex is developing a new class of antibody-drug conjugates designed to deliver therapeutic payloads directly to the nucleus of tumor cells and tumor-associated vasculature. The company’s lead asset, AGX101, targets TM4SF1, a protein highly expressed in tumor blood vessels and tumor cells, with limited expression in normal adult tissues.

AGX101 is currently in Phase 1 clinical trials in patients with advanced solid tumors and has demonstrated an exceptional safety profile alongside early signs of clinical activity, including stable disease and tumor shrinkage at higher dose levels.

What Differentiates Angiex

• First-in-Class Nuclear-Delivered ADC Platform — Designed to bypass traditional ADC resistance mechanisms through direct nuclear payload delivery
• Validated Tumor Target (TM4SF1) — Enables dual targeting of tumor vasculature and tumor cells
• Three Complementary Mechanisms of Action — Vascular deprivation, immune activation, and direct tumor cell killing
• Outstanding Safety Profile — No observed adverse effects in primate studies at the highest dose tested
• Early Clinical Validation — On-target pharmacodynamics and emerging tumor response in Phase 1

Event Details

Date: Monday, January 12, 2026
Time: 5:30 – 7:30 PM PST
Location: Fogo de Chão, 201 3rd Street, San Francisco

Attendance is strictly limited and curated.

Important Notes

This meeting is intended for direct and active private investors only.
All attendees must pre-register via this Eventbrite page and complete investor qualification criteria.
All RSVPs are subject to review and approval.

To request investor materials in advance, please contact:
Skylar Rallison — srallison@opus8.com

If you have any questions, feel free to reach out to me directly. I hope you can join us Monday evening.

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Actuated Medical Private Investor Briefing - San Francisco

by CONNECTpreneur Investor Network

SUNDAY, January 11, 2 pm PST

Opus8 is hosting a small, invitation-only private investor briefing during JP Morgan Week featuring Actuated Medical, a medical device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment.

This closed-door session will provide direct access to the Actuated Medical leadership team and an opportunity to review the company’s neuro platform, clinical direction, and upcoming milestones, as well as its broader strategic roadmap.

Company Overview

Actuated Medical is a med device company transforming tools for brain access, biologic therapy delivery, & neural disease treatment. The company also maintains a portfolio of FDA-cleared technologies, providing strategic and financial optionality as it advances its core neuro program.

What Differentiates Actuated Medical

• Large Neurological Opportunity — Platform technology addressing significant unmet needs in neuro procedures

• Proprietary Engineering — Differentiated catheter-based design enabling precision access and delivery

• Clinical Momentum — Active engagement with leading clinicians and academic medical centers

• Strategic Optionality — FDA-cleared assets alongside a focused neuro platform

• Experienced Leadership — Proven device development and commercialization expertise

Event Details

Date: Sunday, January 11, 2026
Time: 2 – 3:30 PM PST
Location: Fogo de Chão, San Francisco

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

If you have any questions, please reach out to me. Hope to see you on Jan 11th!

To request investor materials, contact:
Skylar Rallison — srallison@opus8.com

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

twong@opus8.com

M 703 932 9191

Kick Off JPM Week 2026 with an Exclusive Investor Networking Brunch!

Start your JPM Week experience with an exceptional networking opportunity designed to connect healthcare and life sciences investors with leading biotech and life sciences entrepreneurs.

Why Attend?

• Meet dozens of top-tier investors and influential industry leaders in an intimate, high-value setting.

• Connect with innovative companies driving breakthroughs in healthcare and biotech.

• Expand your network with like-minded professionals, entrepreneurs, and decision-makers.

Hosted annually by CONNECTpreneur and Opus8, this event offers an exclusive chance to build relationships that can shape the future of healthcare and life sciences.

Event Details

📅 Sunday, January 11, 2026

📍 Fogo de Chão Brazilian Steakhouse

201 3rd St Suite 100,

San Francisco, CA 94103

Enjoy light fare and unlimited premium coffee in a relaxed, upscale atmosphere.

Who Should Attend?

• VCs and Accredited investors passionate about healthcare, biotech, and life sciences.

• Entrepreneurs and founders seeking capital and partnerships.

Limited Availability!

This event is highly sought after, with limited spots available to ensure meaningful connections. Reserve your seat today before space runs out!

Take the First Step

Discover the partnerships and insights that could define your 2026.

Register Now to secure your spot and begin your JPM Week on the right note!

Sponsorship and Exhibitor Opportunities

Elevate your brand in front of a highly curated audience of investors and industry leaders. For more information, please contact Skylar Rallison at srallison@opus8.com.

Alphyn Biologics Private Investor Meeting - San Francisco

by CONNECTpreneur Investor Network

SUNDAY, January 11, 9:30am PST

Opus8 is hosting a small, invitation-only investor meeting during JPM Week featuring Alphyn Biologics, a late-clinical dermatology company entering Series B formation.

This closed-door session will provide direct access to the Alphyn management team and an opportunity to review recent clinical progress and upcoming milestones.

Company Overview

Alphyn Biologics is a late-clinical dermatology company developing patented, plant-derived topical therapeutics, led by a Phase 2a–completed asset in Atopic Dermatitis with additional pipeline programs including Molluscum Contagiosum Virus (MCV).

What Differentiates Alphyn

• Huge Market - Multi-target topical mechanism addressing multiple disease drivers

• Excellent Traction - Recently closed on $15 million Series A

• Strong safety and tolerability profile to date

• Patent protection in the U.S. and Europe extending to 2043

• Secured, regulatory-compliant raw material supply

Event Details

Date: Sunday, January 11
Time: 9:30 AM PST
Location: Fogo de Chão, San Francisco

Attendance is limited and curated.

Important Notes

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

To request investor materials, contact:
Skylar Rallison — srallison@opus8.com

Thanks much and all the best,

Tien Wong

CEO

Opus8, Inc.

Dear Investor Friends:

Please join us for this virtual investor-only meeting on Friday, December 19 featuring Intrommune, a consumer health company with a revolutionary approach to peanut allergy prevention.

Intrommune’s patented platform delivers allergens via a familiar routine: brushing your teeth. This toothpaste trains the immune system and helps prevent life-threatening nut allergies.

The Investment Opportunity:

• Amount: $4 million, first closing in December/January

• Minimum investment: $100,000

• Early investors receive preferential terms

• NASDAQ IPO targeted within 36 months

Key Investment Considerations:

Validated Science, Consumer Simplicity - In the Phase 1 study for peanut allergy, patients achieved 97% adherence with 0 dropouts and 0 cases of anaphylaxis

TRACTION - Company is already generating revenue through its distribution channels in November, 2025.

Enormous Market Need with 1st Mover Advantage - Over 33 million Americans suffer from food allergies, with limited treatment options. Intrommune is the only biotech-grade product in a consumer-ready delivery formar.

Attractive Investment Terms - Attractive valuation and terms with incentives.

World Class Leadership - Company is led by some of the top names in the industry

Event Details:

Location: Online via Zoom

Date: Friday, December 19 | 11:30am EST

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Don't miss out - RSVP now.

You can request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

All the best,

Tien Wong

CEO

Opus8, Inc.

Come join us in Tysons Corner, VA for a CONNECTpreneur Forum Event like you've never seen before!

CONNECTpreneur is a bi-monthly networking mashup, which has been attended by 30,000+ business leaders over the past 13 years and Is cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Space is very limited at this venue, and we expect another sold out crowd, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- Showcase of emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- We are capping attendance at 200 business leaders, including 75+ angels and private investors, family offices, etc.

- Speakers who are deeply rooted in our community, sharing their insider knowledge and showcasing the innovation thriving in our region.

- Heavy networking before, during, and after the event

Festive attire is encouraged!🎄

Back by popular demand! Join us for an exclusive CONNECTpreneur Master Class featuring Anthony Millin, CEO/Co-Founder of My NEXT Raise

When:

Thursday, December 11, 2025

11:30 am ET

Description:

In today’s fast-moving investment landscape, raising capital is more competitive than ever. Founders who succeed aren’t just lucky — they’re strategic, prepared, and investor-ready. Join Anthony Millin — a trusted authority with decades of experience as a venture investor, startup attorney, serial entrepreneur, and CEO/Co-Founder of My NEXT Raise — for this high-impact Masterclass. Anthony has raised capital himself, advised hundreds of founders, and built a platform designed specifically to help startups succeed.

In this session, you'll gain:

• Authority-backed insights from someone who’s been in the fundraising trenches — and won

• A behind-the-scenes look at what top investors actually look for (most founders miss this)

• Proven tools and strategies from My NEXT Raise, used by hundreds of successful startups

• A clear, step-by-step path to becoming investor-ready — with legal and business essentials aligned

• An opportunity to connect with Anthony and ask questions directly

• Access to exclusive fundraising tools — only available to attendees

Join us again to dive deeper into these critical issues and more as 2025 comes to a close. What will the fundraising market look like in 2026? How do founders need to adjust? Don’t miss this important Masterclass!

Whether you're preparing for your first seed round or scaling toward Series A, this session will arm you with the knowledge, credibility, and confidence to raise capital effectively — and close with conviction.

Dear Investor Friends:

Please join us for an invitation only virtual private investor meeting on Zoom, featuring ARC Medical, on Wednesday, December 10th, 2025.

ARC is one of the most exciting life sciences companies we have seen! ARC significantly improves surgical patient recovery by preventing internal adhesions, the most common complication in knee, shoulder, gynecological and abdominal surgeries.

ARC is completing its $5M raise by mid-January, after which they plan to accept a $25 million term sheet for their B round.

Key Investment Considerations

• Massive Markets: 11 million patients yearly and a TAM $11 billion

• Excellent Efficacy and Clinical Data: for company’s lead products for knee and shoulder surgeries

• Strong IP Provide Exclusivity: multiple patents granted that provide exclusivity for the company’s products through 2039 and beyond.

• Great Fundrasing traction: ARC has already raised $39 million ($21M in equity and $18M in non-dilutive revenue and grants), and will close the current round in a matter of weeks.

• Unicorn-level Exit Potential: representing a 20X return based on comparable companies in the wound healing arena.

• World Class Team: has designed, developed multi $billion products for companies including J&J, Stryker, Smith+Nephew, Amgen and Moderna

Event Details:

📍Online via Zoom

🗓 December 10, 2025 | 11:30 AM EST

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

This event is exclusively limited to invited UHNW/HNW investors, family offices, accredited investors, and financial advisors.

Request investor materials by contacting Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

CONNECTpreneur Master Class:

Hyper-Accelerate Your Business Value

The Inside Secrets to Explosive Valuation Acceleration

Steve Little, CEO of Zero Limites Ventures

When:

Friday, December 5, 2025

11:30 am ET

Description:

Join a select group of ambitious founders and savvy investors for a high-impact master class designed to give you an insider’s edge on valuation acceleration.

You'll learn how to leverage 24 specific key business valuation accelerators so you can maximize returns on investment, boost acquisition multiples AND minimize equity dilution at capital raise.

This is a deep dive into the proven valuation growth strategies and tactics used by Zero Limits Ventures supporting the highest-performing companies—so you know what to prioritize to maximize enterprise valuation and how to position your company for a successful 10x, 20x, 30x or 50x acquisition.

You’ll hear from a 10-time serial entrepreneur with 6 of his own high nine-figure exits and who has guided 470 other firms to 10x, 20x and 100x valuation increases, raised over $3B in investment capital, and made a significant contribution to advancing humanity around the world.

You’ll discover and learn:

• Why, regardless of stage (idea, seed, early, ‘A’, ‘B’, ‘C’ or beyond), it’s never too early to develop a valuation growth and exit strategy (even if you're not ready to sell).

• The 'One Simple Rule' of business valuation acceleration that Steve has used countless times to repeatedly generate astonishing valuation growth results over 470 times.

• The 24 key factors to value acceleration that determine your path to building a thriving, prosperous and successful business that delivers a lifetime of financial returns.

• How the rules of valuation growth have changed, and how you can use that discovery to capture an unshakable strategic advantage for high-multiple success.

• How to take advantage of 4 critical timing factors that determine not only the probability of a successful exit but that also dictate the optimum timing of that life changing event.

• How to avoid the ONE most heartbreaking mistake that typically robs founders of the massive returns they deserve

• How Zero Limits Ventures can help you pilot your enterprise to maximize valuation, whether you're raising investment capital, positioning for exit, or just want to build a valuable asset to support your legacy.

• How Zero Limits Capital provides early stage companies direct venture capital investment and supports them to realizing extraordinarily high valuation acceleration right out of the gate.

This Masterclass is designed to reveal valuation accelerating actions you can take right away to immediately accelerate the value of your enterprise

Seats are limited to maintain a high-caliber peer group and foster real discussion. Previous sessions have sold out quickly.

Come join us in Baltimore, MD for a CONNECTpreneur Forum event like you've never seen before! This event is set to be a smaller and more exclusive gathering, tailor-made for premium networking and connecting entrepreneurs with seasoned investors. With CONNECTpreneur's track record of fostering valuable connections and driving investment opportunities, attendees can expect an unparalleled platform to fuel their business growth.

Tickets will go FAST, as we only have a VERY limited number available!

CONNECTpreneur is a bi-monthly networking mashup, which has been attended by over 40,000 business leaders since 2011.

Space is very limited at this venue, and we expect another Sold Out crowd, so there will be no on-site registration.

All attendees must be pre-registered.

Continental breakfast and unlimited coffee will be provided.

Program Highlights:

- We are capping attendance at 200 business leaders, including 75+ angel investors and accredited private investors, family offices, VCs, etc.

- Investor and VIP Speakers who are deeply rooted in our community, sharing their insider knowledge and showcasing the innovation thriving in our region.

- Heavy networking before, during, and after the event

Company Showcase:

We will have a Rocket Pitch session with 8-12 emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts. Companies will be introduced by:

ANTHONY MILLIN - Founder and Co-Chair, NEXT, powered by Shulman Rogers

DEBBIE CLINE - Founder & Chief of Customer Success, Buzzy Rocket

SPEAKERS

S. TIEN WONG - CEO, Opus8; Founder, Big Idea CONNECTpreneur Forum

ALEX TRIANTIS, DEAN, Johns Hopkins Carey Business School

HARRY COKER, JR. (Invited), Secretary of Commerce, Maryland Department of Commerce

KELLY SCHULZ, CEO, Maryland Tech Council

TROY LEMAILE-STOVALL, CEO, TEDCO

TASHA CORNISH, Executive Director, Cybersecurity Association

CHRIS FREW, Founder, BioBuzz

CONNECTpreneur Master Class:

AI Marketing Shortcuts

How Smart Founders Get Traction Fast

Victoria Collins and Debbie Cline of Buzzy Rocket

When:

Thursday, November 13, 2025

11:30 am ET

Description:

Learn to leverage AI to market faster, spend smarter, and out-market your competition. AI has changed the game for startups, putting powerful marketing tools within every founder’s reach. But while AI can help you move faster, it can’t replace smart strategy.

In this fast-paced masterclass, Buzzy Rocket reveals how early-stage startups can use AI to research audiences, craft messages, and build momentum and why the biggest wins come when you combine smart tools with proven marketing expertise. Walk away with a set of AI shortcuts you can use immediately, plus a clear roadmap for scaling your startup’s marketing the right way.

Attendees will learn how to:

• Use AI strategically for marketing, not blindly

• Automate their marketing intelligently

• Leverage a set of AI marketing shortcuts that they can use immediately

Seats are limited to maintain a high-caliber peer group and foster real discussion. Previous sessions have sold out quickly.

Dear Investors,

In-space manufacturing is emerging as the cornerstone of the next industrial revolution, and we are inviting you to be part of this ground-breaking transformation shaping the space economy.

Join us for a private investor reception on Wednesday, October 15, 5:30 pm – 8:00 pm EDT at The Capital Grille in Washington DC. Gain access to the next frontier of orbital R&D and manufacturing—transforming bold visions into real-world impact.

At Space Phoenix Systems (SPS), we’re building the logistics backbone for microgravity research and manufacturing in space. Our end-to-end launch and return services dramatically lower the cost and complexity of accessing low Earth orbit, removing key barriers for innovators in the space economy. By streamlining missions and providing fully managed solutions, we make space-based R&D and production not just possible - but practical.

Our advanced infrastructure is purpose-built for microgravity research and in-space manufacturing—optimizing mission architecture to reduce payload deployment and return costs.

Why you should attend:

• Meet Andrew Parlock & Team – Hear from the visionary behind revolutionizing space logistics to enable accessible, cost-effective orbital R&D and manufacturing.

• Seize a Multi-Trillion Dollar Opportunity – Gain insight into the rapidly expanding orbital economy.

• Strategic Partnerships – Learn about our strong alliances across government, industry, and academia.

• Market Traction and Growth Trajectory

What sets us apart:

• The only cargo-focused, high-cadence, on-demand space logistics fleet in North America—among only a handful worldwide.

• Return-trip Space Cargo Delivery – fast, economical, and reliable.

• Infrastructure designed to simplify access to LEO, making it reliable, repeatable, and economically viable for scientific and industrial applications alike.

Investment Opportunity:

• Raising $7.5M: SPS is raising $7.5M in equity at a pre-money valuation of $40M. Use of proceeds from the $7.5M financing include R&D, Operating, Launch, and Sales & Marketing, focus and implementation of SPS go-to-market model, and expansion plan.

• Raised to Date: SPS has raised $4.0M in equity and awards. Market traction includes a $300M pipeline, 9 signed Letters of Intent, near-term partnership announcements, and $105M confirmed contract with the US Department of War.

• Potential $ Million Exit: representing a 10-15X return with fully operable service fleet

Space isn’t that hard—when you have the right partner. SPS removes critical bottlenecks, streamlining missions so innovators can focus on discovery, not logistics.

Event Details:

Location: The Capital Grille

Address: 1861 International Dr,

McLean, VA 22102

Date: October 15, 2025

Time: 5:30 PM EDT

We look forward to meeting you in person and sharing this transformative opportunity with you.

This event is exclusively limited to invited family offices, accredited investors, and financial advisors.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Request investor materials by contacting Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

CONNECTpreneur INVESTOR Network: Virtual Meeting

Thursday, October 30, 2025, 11am ET

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

We will email you the Zoom link on the evening of October 29th, as well as the morning of October 30th.

About this Meeting:

CONNECTpreneur prides itself on having the largest community of accredited investors, VCs, private investors, and angels.

This 1 hour CONNECTpreneur INVESTOR Network Virtual Meeting is an exclusive, investors-only virtual meeting featuring curated 4-minute pitches from top early-stage ventures. This closed-door session brings together accredited investors, VCs, angels, and private capital to discover new opportunities. Join us for a focused, private Zoom meeting that streamlines deal flow and encourages active investment discussions.

Program Highlights:

• Exclusive Investor-Only Access– A private, closed-door gathering for accredited investors, VCs, angels, and family offices. The only attendees at this meeting will be the presenters and investors.

• Curated Company Presentations – Handpicked, early-stage ventures showcase their opportunities to an investor-only audience.

• High-Value Deal Flow – Direct access to innovative startups and ventures seeking capital.

• Direct Investor Networking– Connect and build relationships with other investors in a trusted environment.

• Focused Format – No distractions. Just quality presentations and meaningful investor interactions.

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor meeting featuring Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapies that resolve systemic inflammation — unlocking the healthspan, longevity revolution.

Sen-Jam’s proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) platform pairs well-characterized NSAIDs with immune modulators (e.g., mast cell stabilizers) to shut down upstream inflammatory cascades. By targeting inflammation and neuroinflammation at the source, Sen-Jam is advancing novel combination therapeutics across pain and CNS, respiratory/critical care support, metabolic disease, addiction, and healthy aging.

This elegant, de-risked approach bridges biotech rigor with scalable clinical utility — positioning Sen-Jam as a category creator in systemic inflammation resolution.

The Investment Opportunity:

• Now raising: $1.3M

• Minimum investment: $25,000 (lower amounts may be considered at Management’s discretion)

• Early participation: Investors within 30 days receive preferential terms

• Path to scale: 505(b)(2) strategy leveraging existing safety data; near-term clinical catalysts
  

Why Sen-Jam?

Validated Science, Clinical Momentum

• SJP-001 entering Phase 2 for alcohol-induced inflammation (targeting upstream drivers of pain and systemic stress).

• SJP-002C, an innovative anti-inflammatory therapy for respiratory inflammation, recently completed a Phase 2 study with Duke University and this year expanded therapeutic value into Metabolic Disorders including Obesity/MASH

• Platform supported by scientific publications/data packages and 505(b)(2) pathway advantages.

Massive, Underserved Need

• Inflammation and neuroinflammation are the common axis across multi-billion-dollar markets: age-related diseases, pain/CNS, infectious/respiratory, metabolic (metaflammation), addiction, and longevity (inflammaging(. The opportunity is to move medicine from symptomatic relief to systemic resolution.

First-Mover Advantage

• A platform approach that modulates multiple inflammatory pathways (NF-κB, TLR4, cytokines, PG/LT/histamine) to address central sensitization and neuroinflammatory drivers — a differentiated route to durable clinical impact.

Experienced Leadership

• Jackie Iversen, R.Ph., MS (Co-founder & Chief Clinical Officer) — inventor of PAIR technology platform, visionary pharmacist and veteran of pharmacokinetics, pain management and clinical strategy.

• Jim Iversen (CEO & Co-Founder) — seasoned successful entrepreneur with over $80M in exits, YPO change maker and business strategist with value creation at the core

• Supported by a multidisciplinary advisory network across immunology, neuroscience, longevity, and regulatory strategy.
  

Why You Should Attend:

This is a rare opportunity to back a de-risked, platform-scale inflammation company with near-term readouts and multi-indication upside — and to meet the team shaping the next chapter of pain, CNS, and longevity care.

Join a select group of investors for an insider’s view into Sen-Jam’s pipeline, clinical milestones, and commercialization strategy.

Event Details – Strictly Limited:

Location: Online via Zoom

Date: October 29, 2025

Time: 11:30am EDT

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring how resolving systemic inflammation can unlock the next era of healthspan and clinical value.

Warm regards,

Tien Wong

CEO

The Opus8 Team

Dear Investors,

Global demand for wood products is projected to quadruple by 2050, while traditional hardwoods—such as cedar, redwood, ash, and birch—are increasingly constrained by pests, drought, and climate change. The need for sustainable, scalable alternatives has never been greater.

World Tree is meeting that need.

That’s why we’re excited to invite you to a private, invitation-only investor reception on October 23 at 5:30 PT in San Francisco, CA, featuring World Tree, a sustainable lumber company growing the only regenerative hardwood supply in North America.

World Tree is the largest grower of paulownia trees in the Americas, a non-invasive, renewable hardwood with fast growth and the highest strength-to-weight ratio of any wood.

The Investment Opportunity

World Tree is raising $3.5M in additional Series A equity:

• Investment minimum: $50,000 (smaller amounts accepted at the company’s discretion)

• Already raised: $4.5M

• Closing date: November 15

• Capital use: Accelerate lumber sales, targeting $30M annual revenue by 2029. Develop institutional projects, scaling our forestry assets to more than 100,000 acres.

Why World Tree?

Proven traction and scale:

• Over 7,000 acres of trees planted across more than 375 farms.

• More than $300M in assets in the ground and under management.

• First large-scale harvests scheduled to begin in 2026, with buyers already secured

• $17M raised in non-dilutive capital

• Already selling into this market and have over $5M in annual revenue in the late stages of its sales pipeline.

• Projected to be strongly EBIDTA positive in 2026.

First-mover advantage:

• Only grower of paulownia with large-scale operations in the Americas.

• Nine years of R&D that has developed extensive proprietary growing protocols.

• Untapped North American market for paulownia lumber.

Massive market:

• Targeting a North American lumber market valued at $170B

• The lumber market is facing unprecedented supply pressure from climate change, global conflict, and overharvesting, even as demand continues to surge.

Unique product:

• One of the fastest-growing trees in the world, maturing in 8–12 years—3x quicker than many commercial hardwoods. It regrows after harvest up to 5x, reducing replanting costs and increasing yield per acre.

• Lightweight, dimensionally stable, workable wood that is ideal for furniture, millwork and cabinetry, molding, siding, fencing, musical instruments, and marine products.

• Sequesters carbon at nearly 4x the rate of other commercial species.

• Received a rare Class A fire-resistance rating (the highest rating possible). Only four woods (including paulownia) have achieved this without any chemical treatments, making paulownia highly desirable for construction uses.

Why You Should Attend

This dinner offers investors a private look at how World Tree is scaling sustainable timber production and positioning itself for near-term growth milestones. You’ll meet the company’s CEO and explore how this equity raise offers an opportunity to invest in real assets with both a strong financial and environmental upside.

Event Details

Location: Fogo de Chão Brazilian Steakhouse

201 3rd St Suite 100, San Francisco, CA 94103

Date: October 23, 2025

Time: 5:30 pm PT

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Request investment materials by contacting Skylar Rallison at srallison@opus8.com.

We look forward to hosting you and exploring this rare opportunity to build the future of sustainable lumber.

Warm regards,

Tien Wong

CEO

Opus8, Inc.

Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor reception featuring Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapies that resolve systemic inflammation — unlocking the healthspan, longevity revolution.

Sen-Jam’s proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) platform pairs well-characterized NSAIDs with immune modulators (e.g., mast cell stabilizers) to shut down upstream inflammatory cascades. By targeting inflammation and neuroinflammation at the source, Sen-Jam is advancing novel combination therapeutics across pain and CNS, respiratory/critical care support, metabolic disease, addiction, and healthy aging.

This elegant, de-risked approach bridges biotech rigor with scalable clinical utility — positioning Sen-Jam as a category creator in systemic inflammation resolution.

The Investment Opportunity:

• Now raising: $1.3M

• Minimum investment: $25,000 (lower amounts may be considered at Management’s discretion)

• Early participation: Investors within 30 days receive preferential terms

• Path to scale: 505(b)(2) strategy leveraging existing safety data; near-term clinical catalysts
  

Why Sen-Jam?

Validated Science, Clinical Momentum

• SJP-001 entering Phase 2 for alcohol-induced inflammation (targeting upstream drivers of pain and systemic stress).

• SJP-002C, an innovative anti-inflammatory therapy for respiratory inflammation, recently completed a Phase 2 study with Duke University and this year expanded therapeutic value into Metabolic Disorders including Obesity/MASH

• Platform supported by scientific publications/data packages and 505(b)(2) pathway advantages.

Massive, Underserved Need

• Inflammation and neuroinflammation are the common axis across multi-billion-dollar markets: age-related diseases, pain/CNS, infectious/respiratory, metabolic (metaflammation), addiction, and longevity (inflammaging(. The opportunity is to move medicine from symptomatic relief to systemic resolution.

First-Mover Advantage

• A platform approach that modulates multiple inflammatory pathways (NF-κB, TLR4, cytokines, PG/LT/histamine) to address central sensitization and neuroinflammatory drivers — a differentiated route to durable clinical impact.

Experienced Leadership

• Jackie Iversen, R.Ph., MS (Co-founder & Chief Clinical Officer) — inventor of PAIR technology platform, visionary pharmacist and veteran of pharmacokinetics, pain management and clinical strategy.

• Jim Iversen (CEO & Co-Founder) — seasoned successful entrepreneur with over $80M in exits, YPO change maker and business strategist with value creation at the core

• Supported by a multidisciplinary advisory network across immunology, neuroscience, longevity, and regulatory strategy.
  

Why You Should Attend:

This is a rare opportunity to back a de-risked, platform-scale inflammation company with near-term readouts and multi-indication upside — and to meet the team shaping the next chapter of pain, CNS, and longevity care.

Join a select group of investors for an insider’s view into Sen-Jam’s pipeline, clinical milestones, and commercialization strategy.

Event Details – Strictly Limited:

Location:

Fogo de Chão Brazilian Steakhouse

40 West 53rd

Manhattan, NY 10019

Date: October 20, 2025

Time: 5:30pm EDT

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring how resolving systemic inflammation can unlock the next era of healthspan and clinical value.

Warm regards,

Tien Wong

CEO

The Opus8 Team

Dear Investor,

Join us for an invitation only investor dinner, featuring ARC Medical, at The Capital Grille on Thursday, October 16th, 2025.

ARC is significantly improving surgical patient recovery by preventing internal adhesions, the most common surgical complication.

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Event Details:

📍 The Capital Grille,

8038 - Rockefeller Center,

120 W 51st St.

New York, NY 10020

🗓 October 16, 2025 | 5:30 PM EDT

Why Attend?

Meet ARC’s leadership team and learn how their liquid devices, JOCOAT™ and IPCOAT™, are transformative breakthroughs for surgical patients’ recovery, care and experience in knee, shoulder, gynecological and abdominal surgeries.

Connect with fellow sophisticated healthcare investors in a private setting.

Why ARC Medical?

• Large Unmet Medical Needs and Markets : Surgical adhesions cause chronic pain and suffering, immobility, and infertility – with 11 million surgery patients yearly and a total addressable market of $11 billion annually.

• Compelling Efficacy and Safety Clinical Data : for the company’s JOCOAT™ in orthopedic knee and shoulder surgery patients (N=17) and IPCOAT™ in a gynecological and abdominal safety clinical trial (N=76).

• Strong Patents Provide Exclusivity : ARC has 5 composition of matter patents granted in each of the US and Japan and additional patents in other key territories that provide exclusivity for the company’s JOCOAT™ and IPCOAT™ through 2039 and beyond.

• Experienced Leadership Team : has “been there, done that” including designing and developing a Boston Scientific partnered stent that resulted in first year sales of $2 billion; has relevant experience at J&J, Stryker, Smith+Nephew, Amgen and Moderna; and designed and ran the clinical trials resulting in the approvals and commercialization of 3 previous generation anti-surgical adhesion devices.

Momentum and Near-Term Milestones:

1. ARC’s JOCOAT™ clinical trial in knee ACL repair surgery patients is underway (N=70).

2. ARC is initiating its IPCOAT™ clinical trial in gynecological endometriosis surgery patients (N=21).

3. Topline data from both clinical trials are expected in 2026.

4. Initial approvals and sales are expected for JOCOAT™ and IPCOAT™ in 2027 in select territories including Germany, Kingdom of Saudi Arabia, United Arab Emirates, Australia and Canada.

5. Both clinical trials serve as pilot studies for the US.

What is the Investment Opportunity?

Raising $5M : ARC is now raising $5M in equity at a pre-money valuation of $45M. Use of proceeds from the $5M financing include providing 2+ years of runway, completing a partnership with a large Japanese company for Japan (currently negotiating the term sheet), and increasing the number of patients in the 2 clinical trials outlined below.

Raised to Date : ARC has raised $21M in equity and an additional $18M in non-dilutive revenues and grants. This funding has taken the company to run outside of US pivotal clinical trials, with anticipated near term clinical milestones and near term partnering announcements.

Potential $ Billion Exit : representing a 20X return based on comparable companies in the wound healing arena.

This event is exclusively limited to invited family offices, accredited investors and financial advisors.

Request investor materials by contacting: Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

Dear Investor,

Join us for an invitation only investor dinner, featuring ARC Medical, at Fleming’s Prime Steakhouse & Wine Bar on Tuesday, October 14th, 2025.

ARC is significantly improving surgical patient recovery by preventing internal adhesions, the most common surgical complication.

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Event Details:

📍 Fleming’s Prime Steakhouse & Wine Bar,

180 El Camino Real G-2,

Palo Alto, CA 94304

🗓 October 14, 2025 | 5:30 PM PDT

Why Attend?

Meet ARC’s leadership team and learn how their liquid devices, JOCOAT™ and IPCOAT™, are transformative breakthroughs for surgical patients’ recovery, care and experience in knee, shoulder, gynecological and abdominal surgeries.

Connect with fellow sophisticated healthcare investors in a private setting.

Why ARC Medical?

• Large Unmet Medical Needs and Markets : Surgical adhesions cause chronic pain and suffering, immobility, and infertility – with 11 million surgery patients yearly and a total addressable market of $11 billion annually.

• Compelling Efficacy and Safety Clinical Data : for the company’s JOCOAT™ in orthopedic knee and shoulder surgery patients (N=17) and IPCOAT™ in a gynecological and abdominal safety clinical trial (N=76).

• Strong Patents Provide Exclusivity : ARC has 5 composition of matter patents granted in each of the US and Japan and additional patents in other key territories that provide exclusivity for the company’s JOCOAT™ and IPCOAT™ through 2039 and beyond.

• Experienced Leadership Team : has “been there, done that” including designing and developing a Boston Scientific partnered stent that resulted in first year sales of $2 billion; has relevant experience at J&J, Stryker, Smith+Nephew, Amgen and Moderna; and designed and ran the clinical trials resulting in the approvals and commercialization of 3 previous generation anti-surgical adhesion devices.

Momentum and Near-Term Milestones:

1. ARC’s JOCOAT™ clinical trial in knee ACL repair surgery patients is underway (N=70).

2. ARC is initiating its IPCOAT™ clinical trial in gynecological endometriosis surgery patients (N=21).

3. Topline data from both clinical trials are expected in 2026.

4. Initial approvals and sales are expected for JOCOAT™ and IPCOAT™ in 2027 in select territories including Germany, Kingdom of Saudi Arabia, United Arab Emirates, Australia and Canada.

5. Both clinical trials serve as pilot studies for the US.

What is the Investment Opportunity?

Raising $5M : ARC is now raising $5M in equity at a pre-money valuation of $45M. Use of proceeds from the $5M financing include providing 2+ years of runway, completing a partnership with a large Japanese company for Japan (currently negotiating the term sheet), and increasing the number of patients in the 2 clinical trials outlined below.

Raised to Date : ARC has raised $21M in equity and an additional $18M in non-dilutive revenues and grants. This funding has taken the company to run outside of US pivotal clinical trials, with anticipated near term clinical milestones and near term partnering announcements.

Potential $ Billion Exit : representing a 20X return based on comparable companies in the wound healing arena.

This event is exclusively limited to invited family offices, accredited investors and financial advisors.

Request investor materials by contacting: Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

Dear Investors,

In-space manufacturing is emerging as the cornerstone of the next industrial revolution, and we are inviting you to be part of this ground-breaking transformation shaping the space economy.

Join us for a private investor reception on Thursday, October 9, 5:30 pm – 8:00 pm PDT at Fleming’s Prime Steakhouse & Wine Bar in Palo Alto. Gain access to the next frontier of orbital R&D and manufacturing—transforming bold visions into real-world impact.

At Space Phoenix Systems (SPS), we’re building the logistics backbone for microgravity research and manufacturing in space. Our end-to-end launch and return services dramatically lower the cost and complexity of accessing low Earth orbit, removing key barriers for innovators in the space economy. By streamlining missions and providing fully managed solutions, we make space-based R&D and production not just possible - but practical.

Our advanced infrastructure is purpose-built for microgravity research and in-space manufacturing—optimizing mission architecture to reduce payload deployment and return costs.

Why you should attend:

• Meet Andrew Parlock & Team – Hear from the visionary behind revolutionizing space logistics to enable accessible, cost-effective orbital R&D and manufacturing.

• Seize a Multi-Trillion Dollar Opportunity – Gain insight into the rapidly expanding orbital economy.

• Strategic Partnerships – Learn about our strong alliances across government, industry, and academia.

• Market Traction and Growth Trajectory

What sets us apart:

• The only cargo-focused, high-cadence, on-demand space logistics fleet in North America—among only a handful worldwide.

• Return-trip Space Cargo Delivery – fast, economical, and reliable.

• Infrastructure designed to simplify access to LEO, making it reliable, repeatable, and economically viable for scientific and industrial applications alike.

Investment Opportunity:

• Raising $7.5M: SPS is raising $7.5M in equity at a pre-money valuation of $40M. Use of proceeds from the $7.5M financing include R&D, Operating, Launch, and Sales & Marketing, focus and implementation of SPS go-to-market model, and expansion plan.

• Raised to Date: SPS has raised $4.0M in equity and awards. Market traction includes a $300M pipeline, 9 signed Letters of Intent, near-term partnership announcements, and $105M confirmed contract with the US Department of War.

• Potential $ Million Exit: representing a 10-15X return with fully operable service fleet

Space isn’t that hard—when you have the right partner. SPS removes critical bottlenecks, streamlining missions so innovators can focus on discovery, not logistics.

Event Details:

Location: Fleming’s Prime Steakhouse & Wine Bar

Address: 180 El Camino Real G-2,

Palo Alto, CA 94304

Date: October 9, 2025

Time: 5:30 PM PDT

We look forward to meeting you in person and sharing this transformative opportunity with you.

This event is exclusively limited to invited family offices, accredited investors, and financial advisors.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Request investor materials by contacting Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

Dear Esteemed Investor,

We are pleased to invite you to an exclusive, invitation-only investor reception on Wednesday, October 8 in Palo Alto featuring i-Lumen Scientific, a ophthalmology company focused on restoring vision in those Dry Age-related Macular Degeneration (Dry-AMD).

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Unlike current pharma-based therapies that merely slow disease progress (vision loss), i-Lumen’s patented, non-invasive ocular stimulation therapy (OST) is designed to improve vision with a ‘physician-delivered therapy’ to help the 200.0M people worldwide suffering from Dry-AMD. i-Lumen’s recently completed i-SIGHT Study demonstrated that 54% of participants had improved vision of 2+ Lines (10+ letters) within 7 treatment days delivered within 2 months and maintained the improvement through 12 months.

With a large unmet market, strong clinical data, and a clear FDA pathway, i-Lumen is positioned to be acquired by a strategic in Ophthalmology as early as 2028, and the $850.0M acquisition of LumiThera by Alcon in 2025 has established a benchmark for energy-based therapeutics to treat Dry-AMD.

Please tap on the link to learn more about the i-Lumen's AMD System i-Lumen Scientific - Retinal Bio-stimulation Therapy for Dry AMD.

The Investment Opportunity:

• Series B raise: $35.0M, with $18.0M committed from Series A Investors

• Valuation: $31.5M pre-money / $69.3M post-money

• Investment Options: Direct - $500K, SPV - $100K

• Use of funds: Pivotal Study, FDA filing, Commercial Readiness

Why Attend

Superior Mechanism of Action Restores Vision

i-Lumen’s proprietary ocular stimulation therapy repolarizes retinal pigment epithelium (RPE) cells and restores photoreceptor cell function, improving visual acuity and slowing disease progression.

• 54% improved BCVA by ≥10 letters and maintained improvement out to 12 mths

• 21% increase in photoreceptor cell light-processing speed

• 14% increase in signal strength generated by photoreceptor cells

Massive, Underserved Market

• 200.0 M people globally suffer with AMD, more than 20.0M in the US alone

• Dry AMD market projected to be $68.0B by 2029

Established Acquisition Benchmark – $850.0M Pre-Revenue Sale

• Alcon acquired LumiThera, Inc. for an estimated $850.0M

• LumiThera’s Velada® is an energy-based device therapy for dry AMD

The LumiThera acquisition underscores the industry’s focus on energy-based therapies like the i-Lumen® AMD System, a scalable physician-based revenue model

Pathway to Exit in 2028

• i-SIGHT2 Pivotal Trial data availability – projected for mid-2027

• Submission to FDA for market clearance – projected for late 2027

• Re-engage ophthalmology targets (Alcon, B+L, J&J, etc.) – projected for 2028

Why Attend:

This is a rare opportunity to invest in a late-stage ophthalmology company with a therapeutic that generates vision improvement an industry known for pre-revenue acquisitions. With validated science, a de-risked FDA strategy, and strong IP, i-Lumen offers the potential for 12–15x return projected within the next 2 to 3 years.

Join us for an insider’s view into how i-Lumen is creating a paradigm shift in vision restoration and meet the leadership team powering this transformation.

Event Details:

Fleming’s Prime Steakhouse & Wine Bar,

180 El Camino Real G-2,

Palo Alto, CA 94304

October 8, 2025 | 5:30 PM PDT

RSVP now to secure your seat and request investor materials by contacting: Skylar Rallison at srallison@opus8.com

We look forward to seeing you in Palo Alto for an evening of groundbreaking science, strategic vision, and investment opportunity.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Thanks much and all the best,

The Opus8 Team

Dear Investors,

In-space manufacturing is emerging as the cornerstone of the next industrial revolution, and we are inviting you to be part of this ground-breaking transformation shaping the space economy.

Join us for a private investor reception on Tuesday, October 7, 5:30 pm – 8:00 pm PDT at Fogo de Chão Brazilian Steakhouse in LA. Gain access to the next frontier of orbital R&D and manufacturing—transforming bold visions into real-world impact.

At Space Phoenix Systems (SPS), we’re building the logistics backbone for microgravity research and manufacturing in space. Our end-to-end launch and return services dramatically lower the cost and complexity of accessing low Earth orbit, removing key barriers for innovators in the space economy. By streamlining missions and providing fully managed solutions, we make space-based R&D and production not just possible - but practical.

Our advanced infrastructure is purpose-built for microgravity research and in-space manufacturing—optimizing mission architecture to reduce payload deployment and return costs.

Why you should attend:

• Meet Andrew Parlock & Team – Hear from the visionary behind revolutionizing space logistics to enable accessible, cost-effective orbital R&D and manufacturing.

• Seize a Multi-Trillion Dollar Opportunity – Gain insight into the rapidly expanding orbital economy.

• Strategic Partnerships – Learn about our strong alliances across government, industry, and academia.

• Market Traction and Growth Trajectory

What sets us apart:

• The only cargo-focused, high-cadence, on-demand space logistics fleet in North America—among only a handful worldwide.

• Return-trip Space Cargo Delivery – fast, economical, and reliable.

• Infrastructure designed to simplify access to LEO, making it reliable, repeatable, and economically viable for scientific and industrial applications alike.

Investment Opportunity:

• Raising $7.5M: SPS is raising $7.5M in equity at a pre-money valuation of $40M. Use of proceeds from the $7.5M financing include R&D, Operating, Launch, and Sales & Marketing, focus and implementation of SPS go-to-market model, and expansion plan.

• Raised to Date: SPS has raised $4.0M in equity and awards. Market traction includes a $300M pipeline, 9 signed Letters of Intent, near-term partnership announcements, and $105M confirmed contract with the US Department of War.

• Potential $ Million Exit: representing a 10-15X return with fully operable service fleet

Space isn’t that hard—when you have the right partner. SPS removes critical bottlenecks, streamlining missions so innovators can focus on discovery, not logistics.

Event Details:

Location: Fogo de Chão Brazilian Steakhouse

Address: 1551 Ocean Ave Suite 105,

Santa Monica, CA 90401

Date: October 7, 2025

Time: 5:30 PM PDT

We look forward to meeting you in person and sharing this transformative opportunity with you.

This event is exclusively limited to invited family offices, accredited investors, and financial advisors.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Request investor materials by contacting Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

Kick Off MedTech Week 2025 with an Exclusive Investor Networking Brunch!

Begin your MedTech Week experience with an exceptional networking opportunity designed to connect medtech and healthcare investors with leading medtech innovators.

Why Attend?

• Engage with top-tier investors and influential industry leaders in an intimate, high-value setting.

• Discover innovative companies driving breakthroughs in medical technology.

• Expand your network with like-minded professionals, entrepreneurs, and decision-makers.

Event Details

• 📅 Sunday, October 5, 2025 at 11am

• 📍Fogo de Chão Brazilian Steakhouse, 668 Sixth Ave, San Diego, CA 92101

• 🍽️ Enjoy light fare and unlimited premium coffee in a relaxed, upscale atmosphere.

Who Should Attend?

• VCs and Accredited investors passionate about medtech, healthcare, and life sciences.

• Entrepreneurs and founders seeking capital and partnerships.

• Sponsors and service professionals working in the medtech space.

Limited Availability!

This event is highly sought after, with limited spots available to ensure meaningful connections. Reserve your seat today before space runs out!

Take the First Step

Discover the partnerships and insights that could define your next year!

👉 Register now to secure your spot and begin your MedTech Week on the right note!

Sponsorship and Exhibitor Opportunities

Elevate your brand in front of a highly curated audience of investors and industry leaders. For more information, please contact Skylar Rallison at srallison@opus8.com.

Dear Investors,

In-space manufacturing is emerging as the cornerstone of the next industrial revolution, and we are inviting you to be part of this ground-breaking transformation shaping the space economy.

Join us for a private investor reception on Monday, September 29, 5:30 pm – 8:00 pm EDT at The Capital Grille in NYC. Gain access to the next frontier of orbital R&D and manufacturing—transforming bold visions into real-world impact.

At Space Phoenix Systems (SPS), we’re building the logistics backbone for microgravity research and manufacturing in space. Our end-to-end launch and return services dramatically lower the cost and complexity of accessing low Earth orbit, removing key barriers for innovators in the space economy. By streamlining missions and providing fully managed solutions, we make space-based R&D and production not just possible - but practical.

Our advanced infrastructure is purpose-built for microgravity research and in-space manufacturing—optimizing mission architecture to reduce payload deployment and return costs.

Why you should attend:

• Meet Andrew Parlock & Team – Hear from the visionary behind revolutionizing space logistics to enable accessible, cost-effective orbital R&D and manufacturing.

• Seize a Multi-Trillion Dollar Opportunity – Gain insight into the rapidly expanding orbital economy.

• Strategic Partnerships – Learn about our strong alliances across government, industry, and academia.

• Market Traction and Growth Trajectory

What sets us apart:

• The only cargo-focused, high-cadence, on-demand space logistics fleet in North America—among only a handful worldwide.

• Return-trip Space Cargo Delivery – fast, economical, and reliable.

• Infrastructure designed to simplify access to LEO, making it reliable, repeatable, and economically viable for scientific and industrial applications alike.

Investment Opportunity:

• Raising $7.5M: SPS is raising $7.5M in equity at a pre-money valuation of $40M. Use of proceeds from the $7.5M financing include R&D, Operating, Launch, and Sales & Marketing, focus and implementation of SPS go-to-market model, and expansion plan.

• Raised to Date: SPS has raised $4.0M in equity and awards. Market traction includes a $300M pipeline, 9 signed Letters of Intent, near-term partnership announcements, and $105M confirmed contract with the US Department of War.

• Potential $ Million Exit: representing a 10-15X return with fully operable service fleet

Space isn’t that hard—when you have the right partner. SPS removes critical bottlenecks, streamlining missions so innovators can focus on discovery, not logistics.

Event Details:

Location: The Capital Grille, Rockefeller Center

Address: 120 W 51st St.

New York, NY 10020

Date: September 29, 2025

Time: 5:30 PM EDT

We look forward to meeting you in person and sharing this transformative opportunity with you.

This event is exclusively limited to invited family offices, accredited investors, and financial advisors.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Request investor materials by contacting Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

Dear Investor,

We are pleased to invite you to an exclusive, invitation-only investor reception on Tuesday, September 30 in New York City featuring i-Lumen Scientific, a ophthalmology company focused on restoring vision in those Dry Age-related Macular Degeneration (Dry-AMD).

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Unlike current pharma-based therapies that merely slow disease progress (vision loss), i-Lumen’s patented, non-invasive ocular stimulation therapy (OST) is designed to improve vision with a ‘physician-delivered therapy’ to help the 200.0M people worldwide suffering from Dry-AMD. i-Lumen’s recently completed i-SIGHT Study demonstrated that 54% of participants had improved vision of 2+ Lines (10+ letters) within 7 treatment days delivered within 2 months and maintained the improvement through 12 months.

With a large unmet market, strong clinical data, and a clear FDA pathway, i-Lumen is positioned to be acquired by a strategic in Ophthalmology as early as 2028, and the $850.0M acquisition of LumiThera by Alcon in 2025 has established a benchmark for energy-based therapeutics to treat Dry-AMD.

Please tap on the link to learn more about the i-Lumen's AMD System i-Lumen Scientific - Retinal Bio-stimulation Therapy for Dry AMD.

The Investment Opportunity:

• Series B raise: $35.0M, with $18.0M committed from Series A Investors

• Valuation: $31.5M pre-money / $69.3M post-money

• Investment Options: Direct - $500K, SPV - $100K

• Use of funds: Pivotal Study, FDA filing, Commercial Readiness

Why i-Lumen?

Superior Mechanism of Action Restores Vision

i-Lumen’s proprietary ocular stimulation therapy repolarizes retinal pigment epithelium (RPE) cells and restores photoreceptor cell function, improving visual acuity and slowing disease progression.

• 54% improved BCVA by ≥10 letters and maintained improvement out to 12 mths

• 21% increase in photoreceptor cell light-processing speed

• 14% increase in signal strength generated by photoreceptor cells

Massive, Underserved Market

• 200.0 M people globally suffer with AMD, more than 20.0M in the US alone

• Dry AMD market projected to be $68.0B by 2029

Established Acquisition Benchmark – $850.0M Pre-Revenue Sale

• Alcon acquired LumiThera, Inc. for an estimated $850.0M

• LumiThera’s Velada® is an energy-based device therapy for dry AMD

The LumiThera acquisition underscores the industry’s focus on energy-based therapies like the i-Lumen® AMD System, a scalable physician-based revenue model

Pathway to Exit in 2028

• i-SIGHT2 Pivotal Trial data availability – projected for mid-2027

• Submission to FDA for market clearance – projected for late 2027

• Re-engage ophthalmology targets (Alcon, B+L, J&J, etc.) – projected for 2028

Why Attend:

This is a rare opportunity to invest in a late-stage ophthalmology company with a therapeutic that generates vision improvement an industry known for pre-revenue acquisitions. With validated science, a de-risked FDA strategy, and strong IP, i-Lumen offers the potential for 12–15x return projected within the next 2 to 3 years.

Join us for an insider’s view into how i-Lumen is creating a paradigm shift in vision restoration and meet the leadership team powering this transformation.

Event Details – Strictly Limited

Location: The Capital Grille

Address: 200 Park Ave, New York, NY 10166

Date: Tuesday, September 30, 2025

Time: 5:30 PM EDT

RSVP now to secure your seat and request investor materials by contacting: Skylar Rallison at srallison@opus8.com

We look forward to seeing you in New York for an evening of groundbreaking science, strategic vision, and investment opportunity.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Thanks much and all the best,

The Opus8 Team

Dear Investors,

In-space manufacturing is emerging as the cornerstone of the next industrial revolution and we are inviting you to be part of this ground-breaking transformation shaping the space economy.

Join us for a virtual investor meeting on Tuesday, September 30 at 11:30AM ET to gain access to the next frontier of orbital R&D and manufacturing—transforming bold visions into real-world impact.

At Space Phoenix Systems (SPS), we’re building the logistics backbone for microgravity research and manufacturing in space. Our end-to-end launch and return services dramatically lower the cost and complexity of accessing low Earth orbit, removing key barriers for innovators in the space economy. By streamlining missions and providing fully managed solutions, we make space-based R&D and production not just possible - but practical.

Our advanced infrastructure is purpose-built for microgravity research and in-space manufacturing—optimizing mission architecture to reduce payload deployment and return costs.

Why you should attend:

• Meet Andrew Parlock & Team – Hear from the visionary behind revolutionizing space logistics to enable accessible, cost-effective orbital R&D and manufacturing.

• Seize a Multi-Trillion Dollar Opportunity – Gain insight into the rapidly expanding orbital economy.

• Strategic Partnerships – Learn about our strong alliances across government, industry, and academia.

• Market Traction and Growth Trajectory

What sets us apart:

• The only cargo-focused, high-cadence, on-demand space logistics fleet in North America—among only a handful worldwide.

• Return-trip Space Cargo Delivery – fast, economical, and reliable.

• Infrastructure designed to simplify access to LEO, making it reliable, repeatable, and economically viable for scientific and industrial applications alike.

Investment Opportunity:

• Raising $7.5M: SPS is raising $7.5M in equity at a pre-money valuation of $40M. Use of proceeds from the $7.5M financing include R&D, Operating, Launch, and Sales & Marketing, focus and implementation of SPS go-to-market model, and expansion plan.

• Raised to Date: SPS has raised $4.0M in equity and awards. Market traction includes a $300M pipeline, 9 signed Letters of Intent, near-term partnership announcements, and $105M confirmed contract with the US Department of War.

• Potential $ Million Exit: representing a 10-15X return with fully operable service fleet

Space isn’t that hard—when you have the right partner. SPS removes critical bottlenecks, streamlining missions so innovators can focus on discovery, not logistics.

Event Details:

Location: Online via Zoom

Date: September 30, 2025

Time: 11:30 AM EDT

We look forward to sharing this transformative opportunity with you. Please note that this meeting is for DIRECT and ACTIVE investors only.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Request investor materials by contacting Skylar Rallison at srallison@opus8.com

Thanks much and all the best,

The Opus8 Team

Disclaimer: This communication is for informational purposes only and is not an offer to sell or a solicitation to buy securities of Space Phoenix Systems (the “Company”). Any offering will be made only to accredited investors or other qualified individuals in accordance with applicable securities laws. Investments in the Company are speculative, involve significant risk, and should only be made after careful review and consultation with your advisors.

Big Idea CONNECTpreneur Forum

Washington DC - IN PERSON

September 11, 2025

CONNECTpreneur Forums are bi-monthly in person networking mashups, which have been attended by over 35,000 business leaders over the past 14 years.

Space is very limited at this venue, and this will another Sold Out in person event, so there will be no on-site registration.

All attendees must be pre-registered.

Program Highlights:

- We are capping attendance at 180+ business leaders, including 75+ angels and private investors, family offices, etc.

- Showcase of Emerging tech companies: A dedicated session for companies to showcase their groundbreaking ideas and innovations to a captivated audience of investors and industry experts.

- Heavy networking before, during, and after the event

Beverages and light fare will be provided.

Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor reception on Monday, September 8 in NYC featuring Intrommune, a consumer health company with a revolutionary approach to allergy prevention.

Intrommune’s patented oral mucosal immunotherapy (OMIT) platform delivers allergenic proteins via a simple, familiar routine: brushing your teeth. This daily-use toothpaste is designed to train the immune system and help prevent life-threatening food allergies—starting with peanuts and tree nuts.

This elegant solution bridges the gap between biotech and consumer health, offering a safe, effective, and scalable approach to a massive and underserved global market.

💡 The Investment Opportunity:

• Now raising $4 million

• Minimum investment: $100,000 (lower amounts may be considered at Management’s discretion)

• Early investors within 30 days receive preferential terms

• NASDAQ IPO targeted within 36 months

Why Intrommune?

Validated Science, Consumer SimplicityI

n the published Phase 1 OMEGA study for peanut allergy, patients achieved 97% adherence with zero dropouts and no cases of anaphylaxis from the therapy—a rare combination of strong clinical results and unmatched user friendliness.

Enormous Market Need

Over 33 million Americans suffer from food allergies, yet treatment options remain limited. Early and consistent food exposure has been shown to decrease food allergies by over 80%. OMIT offers a daily, non-invasive food exposure toothpaste with wide appeal for parents, caregivers, and at-risk individuals.

First-Mover Advantage

No other company combines biotech-grade science with a consumer-ready delivery format—positioning Intrommune as the clear category creator in oral allergy prevention.

Experienced Leadership

CEO Michael Nelson brings decades of operational and financing experience in healthcare, and the company is advised by Dr. Sharon Chinthrajah, a nationally recognized allergy expert.

🎯 Why You Should Attend:

This is a rare opportunity to back a biotech-powered consumer product that’s validated, scalable, and de-risked—and to meet the team behind it in a private setting.

Join a select group of investors for an insider’s view into Intrommune’s next chapter and how this product could become a daily staple for millions of families.

📍 Event Details – Strictly Limited:

Location: The Capital Grille,

200 Park Ave,

New York, NY 10166

Date: September 8, 2025

Time: 5:30pm EDT

This event is exclusively for accredited investors, family offices, and advisors.

📩 RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring this rare convergence of biotech innovation and consumer-scale opportunity.

Warm regards,

Tien Wong

CEO

Opus8, Inc.

Virtual Rocket Pitch + Power Networking by CONNECTpreneur Investor Network

Thursday, August 28, 2025, 11:00am EDT

We will email you the LINK to this special event on the evening of August 27th, as well as the morning of August 28th.

About this Event:

CONNECTpreneur Virtual Rocket Pitch events are the World's Largest investor pitch events, with the greatest number of accredited investors, VCs, private investors and angels.

This will be our 135th event (68th Virtual) over the last 14 years.

CONNECTpreneur is a bi-monthly networking mashup that has been attended by 30,000+ business leaders over the past 14 years. Our events are cited as "The Best Networking Events in the MidAtlantic" by independent media as well as over 70% of surveyed past attendees.

Program Highlights:

- "Virtual Networking" pre and post-program - via Private Message, and Breakout Rooms

- We feature Breakout Rooms after the Pitch portion of the events. Each Breakout Room is hosted by a Presenting Company. Attendees will be able to enter and leave any Breakout Room at their convenience.

- Who will be online? We expect 400+ business leaders, including 150+ CEOs & Founders, as well as 150+ angels & VCs from around the USA.

- "Rocket Pitch" Showcase of promising emerging tech companies.

- These are virtual "Meetings" NOT "webinars". All attendees can see and direct message all other attendees.

- Investor Polling: Investors can indicate their interest in each Presenting Company for post-event follow-up.

- We will publish a full list of all registrants - name, title, and company name to enhance networking.

All attendees must be pre-registered on this Eventbrite site.

Dear Investors,

Bladder cancer has remained one of the most expensive and persistent cancers on Earth—with limited treatment options and staggering recurrence rates.That ends now.

We’re excited to invite you to a private, invitation-only investor reception on Thursday, August 14 at 5:00PM ET in McLean, VA, featuring Combat Medical, a MedTech company revolutionizing the way we treat some of the world’s most expensive and recurring cancers.

Combat Medical is the first and only company to deliver effective, affordable, and tolerable treatment for the world’s most expensive cancers. The Company has developed two CE-marked drug delivery systems that use localized heat-enhanced chemotherapy (HIVEC®) to dramatically improve outcomes in bladder and peritoneal cancer treatment—areas with few options and high recurrence.

This breakthrough platform delivers chemotherapy directly to the tumor site using precision heat, improving drug absorption, immune response (including activation of natural killer cells), and patient comfort, while reducing side effects and impairing tumor growth. Already used in 35+ countries with 100,000+ treatments delivered, Combat is now entering the U.S. market.

The Investment Opportunity:

• Now raising: $5 million Series A

• $2.7 million already committed

• Funds support: $7M pivotal FDA trial and U.S. market entry

• Interim trial results expected end of 2026; final FDA approval targeted for 2029

• Valuation inflection point anticipated following interim data

• Comparable U.S. drug companies with weaker data have gone public at ~$1.8B valuations

• Backed by $20M to date, including $4M in non-dilutive government grants

• Self-funded operations and profitable international sales

Why Combat Medical?

Validated Technology with Global Traction

Combat’s HIVEC® platform has generated strong international commercial momentum, with $4.3M in 2024 revenue and positive EBITDA. The company’s “razorblade” model provides capital equipment free and monetizes single-use kits—90% of revenue—per treatment.

Massive Market with Urgent Need

Bladder cancer is the most expensive cancer to treat per patient. In the U.S. alone, 60,000 new NMIBC cases occur each year, with recurrence rates over 70%. Combat targets a $600M U.S. obtainable market within an $8B global TAM.

First-Mover Advantage with FDA Momentum

Combat has launched its FDA-reviewed HIVEC® Heat bladder trial, with interim data expected by late 2026. The company is uniquely positioned to lead the U.S. market for BCG-unresponsive NMIBC—a patient segment with few effective options.

Proven Team and Strategic Vision

Founded by Edward Bruce-White and Alberto Martinez, Combat combines medical expertise, commercial execution, and a clear path to exit—offering investors both meaningful impact and a de-risked path to value creation.

Why You Should Attend

This is a rare opportunity to back a clinically proven, revenue-generating MedTech platform poised for U.S. expansion, FDA approval, and significant investor upside. Join a select group of investors for a private, inside look at Combat Medical’s next chapter.

PLEASE NOTE: The minimum investment amount is $100,000

Event Details – Limited to Select Investors

📍 Location: The Capital Grille

1861 International Dr.

McLean, VA 22102

📅 Date: Thursday, August 14, 2025

🕔 Time: 5:00 PM ET

⚠️ Exclusive Invite-Only Event – Seats Are Extremely Limited ⚠️

Light fare and refreshments will be served.

This invitation is extended only to accredited investors, family offices, and investment advisors. RSVP now to secure your place.

For details, or to request the executive summary or investment deck, please contact Skylar Rallison at srallison@opus8.com.

Secure your spot today. Spaces are limited and subject to review. We look forward to hosting you and sharing how Combat Medical is changing the future of cancer treatment—one patient, one system at a time.

Best regards,

Tien Wong

CEO

Opus8, Inc.